Reinforcing involvement of NK cells in psoriasiform dermatitis animal model

Surcel,Mihaela; Munteanu,Adriana  Narcisa; Huică,Radu‑Ionuț; Isvoranu,Gheorghița; Pîrvu,Ioana  Ruxandra; Constantin,Carolina; Bratu,Ovidiu; Căruntu,Constantin; Zaharescu,Isadora; Sima,Lucica; Costache,Marieta; Neagu,Monica

doi:10.3892/etm.2019.7967

Reinforcing involvement of NK cells in psoriasiform dermatitis animal model

Authors:
- Mihaela Surcel
- Adriana Narcisa Munteanu
- Radu‑Ionuț Huică
- Gheorghița Isvoranu
- Ioana Ruxandra Pîrvu
- Carolina Constantin
- Ovidiu Bratu
- Constantin Căruntu
- Isadora Zaharescu
- Lucica Sima
- Marieta Costache
- Monica Neagu
View Affiliations

Affiliations: Immunobiology Laboratory, ‘Victor Babes’ National Institute of Pathology, 050096 Bucharest, Romania, Division of Cellular and Molecular Biology and Histology, ‘Carol Davila’ University of Pharmacy and Medicine, 050474 Bucharest, Romania, Doctoral School Medicine, Titu Maiorescu University, 040441 Bucharest, Romania, Research Laboratory, Romvac Company S.A, 077190 Voluntari, Romania, Doctoral School of Biology, Faculty of Biology, University of Bucharest, 050095 Bucharest, Romania
Published online on: August 30, 2019 https://doi.org/10.3892/etm.2019.7967
Pages: 4956-4966
Copyright: © Surcel et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis (Ps) is a chronic inflammatory immune-mediated disease with skin and joint manifestations, characterized by abnormal and rapid proliferation of keratinocytes and infiltration of psoriatic lesions with immune cells. Extensive literature suggests that Ps is a T‑cell mediated disease its pathogenesis being highly related to innate and adaptative immune cells. Although natural killer (NK) cells are involved in the inflammatory process of Ps through pro‑inflammatory cytokine secretion (tumor necrosis factor α, interferon γ), their role in this pathology is not yet fully elucidated. In order to study the involvement of NK subpopulations in the pathogenesis of Ps we used the imiquimod‑based mouse model of psoriasiform dermatitis and NK cells complex phenotype patterns from peripheral blood (PB) and spleen were investigated. Skin inflammation and the disease severity were assessed using in vivo measurements (erythema, desquamation and induration parameters, PASI modified score), splenomegaly assessment and histopathological evaluation. Phenotypic characterization of NK cells in imiquimod (IMQ)‑treated mice was performed by flow cytometry, for both PB and spleen cell suspension. A large panel of surface markers was used: maturation and activation markers [cluster of differentiation (CD)49b, CD11b, CD43, CD27, KLRG1, CD335, CD69, CD28, gp49R, CD45R, CD11c] and markers for cytokine receptors (CD25, CD122, CD132). Our experimental data showed important differences in IMQ‑treated mouse NK cell phenotype as compared to control group. The maturation markers (CD11b, CD43, CD27, KLRG1) were found increased on NK cells, in periphery and spleen, while CD49b+NK1.1+ was significantly lower, and the alterations correlated with the severity of the disease. Our findings reflect the immune engagement toward activatory profile of NK cells and draw attention to evaluating Ps intensity correlated with the mature profile of circulating NK cells.

View Figures

View References

1	Boehncke WH and Schön MP: Psoriasis. Lancet. 386:983–994. 2015. View Article : Google Scholar : PubMed/NCBI
2	Dowlatshahi EA, van der Voort EAM, Arends LR and Nijsten T: Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis. Br J Dermatol. 169:266–282. 2013. View Article : Google Scholar : PubMed/NCBI
3	Parisi R, Symmons DPM, Griffiths CEM and Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team, : Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 133:377–385. 2013. View Article : Google Scholar : PubMed/NCBI
4	Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B and Meyerovitch J: Psoriasis and diabetes: A population-based cross-sectional study. J Eur Acad Dermatol Venereol. 22:585–589. 2008. View Article : Google Scholar : PubMed/NCBI
5	Armstrong AW, Harskamp CT and Armstrong EJ: The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies. Nutr Diabetes. 2:e542012. View Article : Google Scholar : PubMed/NCBI
6	Shah K, Mellars L, Changolkar A and Feldman SR: Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 77:287–292.e4. 2017. View Article : Google Scholar : PubMed/NCBI
7	Kölliker Frers RA, Bisoendial RJ, Montoya SF, Kerzkerg E, Castilla R, Tak PP, Milei J and Capani F: Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metab Endocr. 6:43–54. 2015. View Article : Google Scholar
8	Møller AH, Erntoft S, Vinding GR and Jemec GB: A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas. 6:167–177. 2015.PubMed/NCBI
9	Caruntu C, Boda D, Dumitrascu G, Constantin C and Neagu M: Proteomics focusing on immune markers in psoriatic arthritis. Biomarkers Med. 9:513–528. 2015. View Article : Google Scholar
10	Wolf P, Weger W, Patra V, Gruber-Wackernagel A and Byrne SN: Desired response to phototherapy vs photoaggravation in psoriasis: What makes the difference? Exp Dermatol. 25:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
11	Dalkilic E, Bulbul Baskan E, Alkis N, Gullulu M, Yavuz M, Dilek K, Ersoy A and Yurtkuran M: Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: Analysis of 514 patients. Mod Rheumatol. 22:738–742. 2012. View Article : Google Scholar : PubMed/NCBI
12	Tatu AL and Nwabudike LC: Metoprolol-associated onset of psoriatic arthropathy. Am J Ther. 24:e370–e371. 2017. View Article : Google Scholar : PubMed/NCBI
13	Moriwaki Y, Takada K, Tsuji S, Kawashima K and Misawa H: Transcriptional regulation of SLURP2, a psoriasis-associated gene, is under control of IL-22 in the skin: A special reference to the nested gene LYNX1. Int Immunopharmacol. 29:71–75. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wheatley R, Brooks J, Stumpf B and Boh E: Obesity, diet, and inflammation in psoriasis. J Psoriasis Psoriatic Arthritis. 2:97–101. 2017. View Article : Google Scholar
15	Farkas A and Kemény L: Alcohol, liver, systemic inflammation and skin: A focus on patients with psoriasis. Skin Pharmacol Physiol. 26:119–126. 2013. View Article : Google Scholar : PubMed/NCBI
16	Fry L and Baker BS: Triggering psoriasis: The role of infections and medications. Clin Dermatol. 25:606–615. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zeng J, Luo S, Huang Y and Lu Q: Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 44:863–872. 2017. View Article : Google Scholar : PubMed/NCBI
18	Mrowietz U and Reich K: Psoriasis - new insights into pathogenesis and treatment. Dtsch Arztebl Int. 106:11–18, quiz 19. 2009.PubMed/NCBI
19	Carrascosa JM, Jacobs I, Petersel D and Strohal R: Biosimilar drugs for psoriasis: Principles, present, and near future. Dermatol Ther (Heidelb). 8:173–194. 2018. View Article : Google Scholar : PubMed/NCBI
20	Niculet E, Neculia GV, Tatu AL and Buzia OD: Curcumin-extraction, physical and chemical analysis, formulas and control. basic methods for further research. Mater Plast. 55:672–675. 2018.
21	Nwabudike LC and Tatu AL: Using complementary and alternative medicine for the treatment of psoriasis. A step in the right direction. JAMA Dermatol. Mar 13–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
22	Karczewski J, Dobrowolska A, Rychlewska-Hańczewska A and Adamski Z: New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis. Autoimmunity. 49:435–450. 2016. View Article : Google Scholar : PubMed/NCBI
23	Surcel M, Huica R, Constantin C, Ursaciuc C and Neagu M: Biomarkers insights in psoriasis - Regulatory cytokines. Curr Biomark. 7:3–11. 2017. View Article : Google Scholar
24	Mahil SK, Capon F and Barker JN: Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 38:11–27. 2016. View Article : Google Scholar : PubMed/NCBI
25	Caligiuri MA: Human natural killer cells. Blood. 112:461–469. 2008. View Article : Google Scholar : PubMed/NCBI
26	Dunphy SE, Sweeney CM, Kelly G, Tobin AM, Kirby B and Gardiner CM: Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production. Clin Immunol. 177:43–49. 2017. View Article : Google Scholar : PubMed/NCBI
27	von Bubnoff D, Andrès E, Hentges F, Bieber T, Michel T and Zimmer J: Natural killer cells in atopic and autoimmune diseases of the skin. J Allergy Clin Immunol. 125:60–68. 2010. View Article : Google Scholar : PubMed/NCBI
28	Takahashi H, Amagai M, Tanikawa A, Suzuki S, Ikeda Y, Nishikawa T, Kawakami Y and Kuwana M: T helper type 2-biased natural killer cell phenotype in patients with pemphigus vulgaris. J Invest Dermatol. 127:324–330. 2007. View Article : Google Scholar : PubMed/NCBI
29	Zakka LR, Fradkov E, Keskin DB, Tabansky I, Stern JNH and Ahmed AR: The role of natural killer cells in autoimmune blistering diseases. Autoimmunity. 45:44–54. 2012. View Article : Google Scholar : PubMed/NCBI
30	Bocheńska K, Smolińska E, Moskot M, Jakóbkiewicz-Banecka J and Gabig-Cimińska M: Models in the research process of psoriasis. Int J Mol Sci. 18:E25142017. View Article : Google Scholar : PubMed/NCBI
31	Banerjee S and Kaunelis D: Imiquimod for the treatment of genital warts: A review of clinical effectiveness and cost-effectivenessCADTH Rapid Response Report: Summary with critical appraisal. Canadian Agency for Drugs and Technologies in Health; Ottawa, ON: 2017
32	Bhatta AK, Wang P, Keyal U, Zhao Z, Ji J, Zhu L, Wang X and Zhang G: Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma. Photodiagnosis Photodyn Ther. 23:273–280. 2018. View Article : Google Scholar : PubMed/NCBI
33	Banerjee S and Kaunelis D: Imiquimod for the treatment of actinic keratosis: A review of clinical effectiveness and cost-effectivenessCADTH Rapid Response Report: Summary with critical appraisal. Canadian Agency for Drugs and Technologies in Health; Ottawa, ON: 2017
34	Surcel M, Huică R-I, Munteanu AN, Isvoranu G, Pîrvu IR, Ciotaru D, Constantin C, Bratu O, Căruntu C, Neagu M, et al: Phenotypic changes of lymphocyte populations in psoriasiform dermatitis animal model. Exp Ther Med. 17:1030–1038. 2019.PubMed/NCBI
35	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, . Guide for the Care and Use of Laboratory Animals8th. National Academies Press (US); Washington, DC: 2011
36	van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, et al: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 182:5836–5845. 2009. View Article : Google Scholar : PubMed/NCBI
37	Blasius AL, Barchet W, Cella M and Colonna M: Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med. 204:2561–2568. 2007. View Article : Google Scholar : PubMed/NCBI
38	Isvoranu G, Surcel M, Huică R-I, Munteanu AN, Pîrvu IR, Ciotaru D, Constantin C, Bratu O, Neagu M and Ursaciuc C: Natural killer cell monitoring in cutaneous melanoma - new dynamic biomarker. Oncol Lett. 17:4197–4206. 2019.PubMed/NCBI
39	Abel AM, Yang C, Thakar MS and Malarkannan S: Natural killer cells: Development, maturation, and clinical utilization. Front Immunol. 9:18692018. View Article : Google Scholar : PubMed/NCBI
40	Huntington ND, Tabarias H, Fairfax K, Brady J, Hayakawa Y, Degli-Esposti MA, Smyth MJ, Tarlinton DM and Nutt SL: NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol. 178:4764–4770. 2007. View Article : Google Scholar : PubMed/NCBI
41	Kim J, Lee J, Gonzalez J, Fuentes-Duculan J, Garcet S and Krueger JG: Proportion of CD4+CD49b+LAG-3+ Type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index. J Invest Dermatol. 138:2669–2672. 2018. View Article : Google Scholar : PubMed/NCBI
42	Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E and Walzer T: Maturation of mouse NK cells is a 4-stage developmental program. Blood. 113:5488–5496. 2009. View Article : Google Scholar : PubMed/NCBI
43	Hadad U, Thauland TJ, Martinez OM, Butte MJ, Porgador A and Krams SM: NKp46 clusters at the immune synapse and regulates NK cell polarization. Front Immunol. 6:4952015. View Article : Google Scholar : PubMed/NCBI
44	Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R and Moretta A: Molecular cloning of NKp46: A novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 188:953–960. 1998. View Article : Google Scholar : PubMed/NCBI
45	Dunphy S and Gardiner CM: NK cells and psoriasis. J Biomed Biotechnol. 2011:2483172011. View Article : Google Scholar : PubMed/NCBI
46	Wang LL, Chu DT, Dokun AO and Yokoyama WM: Inducible expression of the gp49B inhibitory receptor on NK cells. J Immunol. 164:5215–5220. 2000. View Article : Google Scholar : PubMed/NCBI
47	Nandi D, Gross JA and Allison JP: CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol. 152:3361–3369. 1994.PubMed/NCBI
48	Georgescu SR, Tampa M, Caruntu C, Sarbu MI, Mitran CI, Mitran MI, Matei C, Constantin C and Neagu M: Advances in understanding the immunological pathways in psoriasis. Int J Mol Sci. 20:E7392019. View Article : Google Scholar : PubMed/NCBI
49	Solberg SM, Sandvik LF, Eidsheim M, Jonsson R, Bryceson YT and Appel S: Serum cytokine measurements and biological therapy of psoriasis - Prospects for personalized treatment? Scand J Immunol. 88:e127252018. View Article : Google Scholar : PubMed/NCBI
50	Guarene M, Pasi A, Bolcato V, Cananzi R, Piccolo A, Sbarsi I, Klersy C, Cacciatore R and Brazzelli V: The presence of HLA-A Bw4-80I KIR ligands could predict ‘Difficult-to-Treat’ psoriasis and poor response to Etanercept. Mol Diagn Ther. 22:471–474. 2018. View Article : Google Scholar : PubMed/NCBI
51	Batani A, Brănișteanu DE, Ilie MA, Boda D, Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy. Exp Ther Med. 15:1241–1246. 2018.PubMed/NCBI
52	Căruntu C, Boda D, Căruntu A, Rotaru M, Baderca F and Zurac S: In vivo imaging techniques for psoriatic lesions. Rom J Morphol Embryol. 55 (Suppl):1191–1196. 2014.PubMed/NCBI
53	Negrei C, Căruntu C, Ginghină O, Burcea Dragomiroiu GTA, Toderescu CD and Boda D: Qualitative and quantitative determination of methotrexate polyglutamates in erythrocytes by high performance liquid chromatography. Rev Chim Buchar. 66:607–610. 2015.